IOL Chemicals & Pharmaceuticals shares gained 1.48% to close at ₹209.55 following the company's announcement of receiving EU REACH registration for its product Triacetin. According to reports from Business Standard, the stock movement reflects investor confidence in the company's regulatory compliance achievements.
The company received registration from the European Chemicals Agency (ECHA) under the European Union's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) framework. As reported by Business Standard, Triacetin is not primarily used as an active drug but functions as a solvent, plasticizer, humectant, formulation aid and flavouring agent depending on the application. The registration enables the company to export its product to European markets, supporting regulatory compliance and market access.
IOL Chemicals & Pharmaceuticals operates in the manufacture of active pharmaceutical ingredients (APIs) and specialty chemicals, with its API portfolio serving major therapeutic categories including pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets. According to Business Standard, the company's diversified product portfolio positions it well for European market expansion opportunities.
The company demonstrated robust financial performance in Q1 FY27, with consolidated net profit jumping 89.8% to ₹64.40 crore compared to ₹33.93 crore in Q1 FY26. As reported by Business Standard, revenue from operations increased 37.08% YoY to ₹756.26 crore in Q1 FY27, reflecting strong operational performance and market demand for the company's pharmaceutical and specialty chemical products.
